Newly diagnosed COVID-19 pneumonia patients admitted to the hospital for treatment High-dose vitamin D, COVID-19 pneumonia, clinical outcomes
Conditions
Interventions
Individuals in the intervention arm are provided a high-dose vitamin D (alfacalcidol 2 mg per day) in addition to standard treatment for COVID-19 pneumonia from enrollment until hospital discharge ,In
Vitamin D ,No vitamin D
Sponsors
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged 18 years and over 2. Diagnosed with COVID-19 pneumonia 3. Agrees to participate in the study
Exclusion criteria
Exclusion criteria: 1. Individuals with gastrointestinal disorders that are unable to take oral medications 2. Diagnosed with sarcoidosis within 1 year 3. Diagnosed with parathyroid gland disease within 1 year 4. Diagnosed with tuberculosis within 1 year 5. Diagnosed with kidney calculi within 1 year 6. Concurrent hypercalcemia with plasma calcium level over 10.6 mg/dL 7. Pregnant or breastfeeding individuals 8. Decline to participate in the study 9. Receipt of palliative therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| COVID-19 pneumonia 30 days Modified ordinal scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization 30 days Medical record review | — |
Countries
Thailand
Contacts
Public ContactPorpon Rotjanapan
Ramathibodi Hospital, Mahidol University
Outcome results
None listed